Merus (NASDAQ:MRUS – Free Report) had its target price lifted by Guggenheim from $57.00 to $93.00 in a research note published on Tuesday, Benzinga reports. Guggenheim currently has a buy rating on the biotechnology company’s stock. Several other equities analysts also recently weighed in on MRUS. Stifel Nicolaus increased their price target on shares of […]